Clinical validation of the Roche cobas HPV test on the Roche cobas 6800 system for the purpose of cervical screening and qualification as a second-generation comparator test.

This study assessed the relative clinical sensitivity and specificity for cervical precancer of the Roche cobas HPV test when processed using the Roche cobas 6800 system using the Roche cobas 4800 HPV test as comparator. Intra- and inter-laboratory reproducibility were evaluated as well. The cobas HPV test run on the cobas 6800 platform demonstrated a relative clinical sensitivity of 1.

Intracellular Proteins Targeting with Bi-Functionalized Magnetic Nanoparticles Following their Endosomal Escape.

The specific targeting of intracellular proteins or organelles by magnetic nanoparticles (MNPs) is a major challenge in nanomedicine, as most MNPs are internalized by cells through endocytosis and remain trapped inside small intracellular vesicles, limiting their ability to reach intracellular components. Furthermore, this phenomenon limits their heating capacity in magnetic hyperthermia, and therefore their potential for cancer treatment. This study presents a strategy based on an original double functionalization of MNPs, with polyhistidine peptides (PHPs) triggering endosomal escape and antibodies targeting specific cytosolic proteins.

Trends in the Management of Oligodendrogliomas: A Multinational and Multidisciplinary Survey Study.

Objective: Oligodendrogliomas present challenges in management despite their favorable prognosis. Optimal therapeutic strategies are not well-established. We aimed to characterize current practice patterns and identify areas of discordance in oligodendroglioma management.

Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib.

We explored the rationale for treating glioblastoma (GBM) with regorafenib. In 103 newly diagnosed GBM patients, we assessed mutations, copy number variants (CNVs), fusions, and overexpression in 46 genes encoding protein kinases (PKs) potentially targeted by regorafenib or its metabolites and performed a functional enrichment analysis to assess their implications in angiogenesis. We analyzed regorafenib's binding inhibitory activity and target affinity for these 46 PKs and focused on a subset of 18 genes inhibited by regorafenib at clinically achievable concentrations and on 19 genes involved in angiogenesis.

Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study.

Introduction: Immune check-point inhibitors (ICI) were a major breakthrough in cancer care, but optimal patient selection remains elusive in most tumors.

Methods: Overall 173 adult patients with metastatic solid tumors candidates to ICI in clinical trials at our Institution were prospectively recruited. Blood samples were collected at cycle 1 (C1D1) and 2 (C2D1) and until the occurrence of progressive disease (PD).